BioSyent Releases Q1 2016 Results
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 05/27/16 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three months ending March 31, 2016. Key highlights include:
"Q1 2016 marked BioSyent''s 23rd consecutive profitable quarter," commented Rene Goehrum, President and CEO of BioSyent. "We continued to strengthen our product portfolio during the quarter, making progress in the commercialization of the CYSVIEW® product in Canada used with blue light cystoscopy and successfully re-launching our urgent care product, Atropine, for use in Aguettant System® pre-filled syringes, to Canadian hospitals. In addition, with our FeraMAX® brand recently being named the #1 Doctor and #1 Pharmacist recommended over-the-counter iron supplement in Canada (Rogers Healthcare Group national survey of 820 physicians and 2,321 pharmacists), we expect further momentum in the pharmaceutical business. Our Q1 2016 Revenue, EBITDA and NIAT results are in line with our plan and reflect our enhanced investment in human capital which primarily occurred last year. With products such as CYSVIEW® and Augettant System® Atropine and Phenylephrine in the early stages of commercialization, and growth in our international business, we expect continued revenue growth through the balance of 2016."
Mr. Goehrum continued, "Our recent signing of an exclusive Distribution Agreement for two new cardiovascular products in Canada with estimated annual peak penetration revenues of $20 million and our establishment of an international subsidiary will support further long-term profitable growth both in Canada and internationally."
The CEO presentation on the Q1 2016 Results is available at the following link:
The Company''s Interim Unaudited Condensed Consolidated Financial Statements and Management''s Discussion & Analysis for the three months ended March 31, 2016 and 2015 will be posted on on May 27, 2016.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit .
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 14,026,087 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contacts:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.05.2016 - 06:00 Uhr
Sprache: Deutsch
News-ID 1437917
Anzahl Zeichen: 2564
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 267 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioSyent Releases Q1 2016 Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioSyent Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
